BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of diaziquone after three different dosage regimens. 1985

T D Bjornsson, and S C Schold, and H S Friedman, and D Schneider, and J M Falletta

Diaziquone (AZQ) is a benzoquinone derivative exhibiting significant effects against CNS tumors. This study investigates the pharmacokinetics of AZQ for three different durations of continuous iv infusions, over 20 mins, 4 hrs, and 6 hrs, in nine patients with CNS malignancies. Total AZQ doses varied from 10 to 20 mg. The average elimination half-life was 37.2 +/- 13.9 mins, the total clearance was 515 +/- 280 ml/min or 11.3 +/- 5.9 ml/min/kg, and the apparent volume of distribution by area was 26.5 +/- 14.7 L or 0.62 +/- 0.50 L/kg. Peak concentrations after the 20-min infusions (three patients) varied from 0.58 to 1.20 micrograms/ml, whereas concentrations during the 4-hr infusions (three patients) varied from 0.02 to 0.37 micrograms/ml, and during the 6-hr infusions (three patients) varied from 0.02 to 0.61 micrograms/ml. These results indicate that concentrations found to exhibit minimum inhibitory effects in in vitro cell studies are achievable during prolonged iv infusions of AZQ.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001388 Aziridines Saturated azacyclopropane compounds. They include compounds with substitutions on CARBON or NITROGEN atoms. Ethyleneimines,Azacyclopropanes, Saturated,Dimethyleneimines,Saturated Azacyclopropanes
D001389 Azirines Unsaturated azacyclopropane compounds that are three-membered heterocycles of a nitrogen and two carbon atoms. Azacyclopropanes, Unsaturated,Unsaturated Azacyclopropanes

Related Publications

T D Bjornsson, and S C Schold, and H S Friedman, and D Schneider, and J M Falletta
Cerebrospinal fluid pharmacokinetics after different dosage regimens of intraventricular etoposide.
December 2003, International journal of clinical pharmacology and therapeutics,
T D Bjornsson, and S C Schold, and H S Friedman, and D Schneider, and J M Falletta
Pharmacokinetics of antimalarials and proposals for dosage regimens.
September 1978, International journal of clinical pharmacology and biopharmacy,
T D Bjornsson, and S C Schold, and H S Friedman, and D Schneider, and J M Falletta
Pharmacokinetics and dosage regimens of anti-inflammatory drugs.
January 1990, Annales de recherches veterinaires. Annals of veterinary research,
T D Bjornsson, and S C Schold, and H S Friedman, and D Schneider, and J M Falletta
Exposure to benzylpenicillin after different dosage regimens in growing pigs.
September 2020, Acta veterinaria Scandinavica,
T D Bjornsson, and S C Schold, and H S Friedman, and D Schneider, and J M Falletta
Plasma dipyridamole concentrations after two different dosage regimens in patients.
January 1983, Journal of clinical pharmacology,
T D Bjornsson, and S C Schold, and H S Friedman, and D Schneider, and J M Falletta
Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens.
March 1988, Antimicrobial agents and chemotherapy,
T D Bjornsson, and S C Schold, and H S Friedman, and D Schneider, and J M Falletta
Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens.
April 2002, Antimicrobial agents and chemotherapy,
T D Bjornsson, and S C Schold, and H S Friedman, and D Schneider, and J M Falletta
Variability of fentanyl pharmacokinetics in man. Computer predicted plasma concentrations for three intravenous dosage regimens.
September 1985, Anaesthesia,
T D Bjornsson, and S C Schold, and H S Friedman, and D Schneider, and J M Falletta
[Clinical pharmacokinetics of mebikar. Computation of individual dosage regimens].
January 1985, Farmakologiia i toksikologiia,
T D Bjornsson, and S C Schold, and H S Friedman, and D Schneider, and J M Falletta
Pharmacokinetics, bioavailability, and dosage regimens of digoxin in dogs.
August 1980, American journal of veterinary research,
Copied contents to your clipboard!